Search results
Author(s):
Joseph A Hill
,
Harriette Van Spall
Added:
1 month ago
In this engaging episode of Masterclass filmed at the ACC, host Dr Harriette Van Spall (McMaster University, Hamilton, CA) sits down with Dr Joseph Hill (UT Southwestern Medical Center, Dallas, TX, US) for a thought-provoking conversation about his career journey, the challenges of medical misinformation, and the critical importance of effective scientific communication.Together, they explore the…
View more
Author(s):
Javed Butler
,
Shelley Zieroth
,
Gianluigi Savarese
Added:
8 months ago
Radcliffe Medical Education, is proud to bring to you this roundtable series which is designed to equip healthcare professionals with the knowledge and tools necessary to identify high-risk patients indicative of worsening HF and to implement effective management strategies. Watch Dr Javed Butler (Baylor Scott & White Health, Dallas, US); Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA)…
View more
Author(s):
Jelena Celutkiene
,
Alexandre Mebazaa
,
Jan Biegus
,
et al
Added:
3 months ago
Author(s):
Marianna Fontana
Added:
5 days ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Author(s):
Stefan Stork
Added:
2 days ago
ESC HF 25 - A secondary analysis of TIM-HF2 showed that patients residing farther from their cardiologist benefited further from remote patient management (RPM).Prof Stefan Störk (University Hospital Wuerzburg, DE) discusses the findings from a pre-specified, secondary analysis of TIM-HF2, investigating the impact of rurality and travel distance on the effectiveness of RPM in patients…
View more
New Insights on HFpEF Treatment
Author(s):
Giulio Balestrieri
,
Raul Limonta
,
Enrico Ponti
,
et al
Added:
1 year ago
Article
Author(s):
Biykem Bozkurt
,
Muthiah Vaduganathan
,
Start date:
Sep 11, 2024
Join us for an unparalleled educational journey dedicated to tackling the complexities of managing HFpEF and HFmrEF patients. This CME-accredited live roundtable is chaired by Dr Biykem Bozkurt (Baylor College of Medicine, US) and features insights from renowned experts Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical…
View more
Author(s):
Harold Bays
Added:
1 year ago
ACC.24 — Dr Harold E Bays, Science Officer for the Obesity Medicine Association, a member of the Board of Trustees of the Obesity Medicine Association, and a member of the Board of Directors of the American Society of Preventive Cardiology, joins us to highlight key information regarding weight loss medications in 2024.Support: This is an independent interview conducted by Radcliffe Cardiology…
View more
Author(s):
James L Januzzi
,
Harriette Van Spall
Added:
1 year ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.
Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or…
View more
Author(s):
Marianna Fontana
Added:
2 years ago
ESC-HFA 23 — We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).
APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1…
View more